FDA authorizes Quest's combined COVID-19 and flu RT-PCR test

By LabPulse.com staff writers

December 8, 2020 -- The U.S. Food and Drug Administration (FDA) said it has authorized Quest Diagnostics' RC COVID-19 +Flu reverse transcription polymerase chain reaction (RT-PCR) Test, the first combined diagnostic test for COVID-19 and influenza A and B to receive that designation using patient samples collected at home.

The kit is available for prescription use with Quest's Self-Collection Kit for COVID-190 + Flu by individuals suspected to have respiratory viral infection consistent with COVID-19 when their healthcare provider deems home collection to be appropriate, according to the FDA. After collecting their sample at home, patients can ship it to a Quest laboratory for analysis.

Quest revenues jump nearly 43% in Q3
Quest Diagnostics announced a jump in its third-quarter revenues on continued demand for COVID-19 testing and the rapid recovery of healthcare utilization....
Anthem, Quest ink partnership
Anthem and Quest Diagnostics have announced a collaboration to improve healthcare delivery for both providers and patients.
Quest wins approval to increase capacity for COVID-19
Quest Diagnostics has received emergency use authorization from the U.S. Food and Drug Administration to test a new laboratory technique that could bolster...
FDA grants first coronavirus clearance for sample pooling to Quest
The U.S. Food and Drug Administration has granted Quest Diagnostics the first emergency use authorization for a SARS-CoV-2 molecular diagnostic for testing...
FDA provides guidance on pooling to boost coronavirus test throughput
The U.S. Food and Drug Administration (FDA) has clarified guidance on the validation of pooled coronavirus testing, in a bid to pave the way for submission...

Copyright © 2020 LabPulse.com

Last Updated ls 12/8/2020 4:14:14 PM